ArticleFrontiers in immunology2020
Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Feasibility and acceptance of transdermal auricular vagus nerve stimulation using a TENS device in females suffering from long COVID fatigue.Wiener klinische Wochenschrift · 2025Trial
- Effect of Zusanli Acupoint Injection with Anisodamine on Postoperative Recovery Quality of Patients Undergoing Bariatric Surgery.Obesity surgery · 2024Trial
- Review
- Differential Improvement in Memory and Executive Functions: Personalized Exercise versus Acupuncture for Mild Cognitive Impairment in Stroke-prone Individuals.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Acupuncture for Major Depressive Disorder: Exploring the Gut Microbiota as a Novel Therapeutic Pathway.Brain and behavior · 2025Article
- Article
- Serum butyrylcholinesterase activity as a predictor of severity and mortality in COVID-19 patients.Scientific reports · 2025Article
- SARS-CoV-2 Main Protease Inhibitors from Natural Product Repository as Therapeutic Candidates for the Treatment of Coronaviridae Infections.Current medicinal chemistry · 2025Review
- Non-invasive vagus nerve stimulation is associated with the reduction in persistent post-concussion symptoms: an observational study.Frontiers in neurology · 2025Article
- Electroacupuncture and vagus nerve stimulation are emerging therapies for hyperemesis gravidarum management.Frontiers in neurology · 2025Review
- Study of Macrophage Activity in Cats with FIP and Naturally FCoV-Shedding Healthy Cats.Pathogens (Basel, Switzerland) · 2024Article
- Effect of physiotherapy on infertility treatment in polycystic ovary syndrome patients.Przeglad menopauzalny = Menopause review · 2024Article
- Non-invasive vagus nerve stimulation in anti-inflammatory therapy: mechanistic insights and future perspectives.Frontiers in neuroscience · 2024Review
- Linear and non‑linear indices of vagal nerve in relation to sex and inflammation in patients with Covid‑19.Biomedical reports · 2023Article
- Article
- Bidirectional crosstalk between the peripheral nervous system and lymphoid tissues/organs.Frontiers in immunology · 2023Review
- Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity-A Prospective, Monocentric Observational Study.Diagnostics (Basel, Switzerland) · 2022Article
- Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease.Biochemical and biophysical research communications · 2022Article
- New Imaging Modality of COVID-19 Pneumonia Developed on the Basis of Alzheimer's Disease Research.International journal of molecular sciences · 2022Article
- COVID-19 in Joint Ageing and Osteoarthritis: Current Status and Perspectives.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory pathway (CAP) is a potential therapeutic strategy. However, there is currently no approved drugs targeting the regulatory pathway. It is evident that nicotine, anisodamine and some herb medicine, activate the CAP and exert anti-inflammation action
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.